CD20
B-cell surface antigen targeted by rituximab, obinutuzumab, and bispecific antibodies (mosunetuzumab, glofitamab, epcoritamab).
No Clinical Trials found for this biomarker.
B-cell surface antigen targeted by rituximab, obinutuzumab, and bispecific antibodies (mosunetuzumab, glofitamab, epcoritamab).
No Clinical Trials found for this biomarker.